Loading...
•
Dec 31, 2025
Apellis Q4 2025 Earnings Report
Apellis reported fourth quarter 2025 net loss of 58951000 on total revenue of 199913000.
Key Takeaways
Apellis generated 199913000 in total revenue in Q4 2025, primarily from SYFOVRE and EMPAVELI product sales, and reported a net loss of 58951000 as operating expenses exceeded gross profit.
Total Q4 revenue reached 199913000, mainly driven by product sales.
SYFOVRE remained the largest contributor to quarterly revenue.
Operating expenses totaled 251055000, exceeding total revenue.
Net loss for the quarter was 58951000.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Apellis expects continued revenue growth from SYFOVRE and EMPAVELI and believes current cash and expected revenues will fund operations to profitability.
Positive Outlook
- Projected revenues expected to fund operations to profitability.
- Strong market position for SYFOVRE in GA.
- Momentum in EMPAVELI kidney disease launch.
- Planned regulatory submission for SYFOVRE prefilled syringe in 2026.
- Advancement of pipeline programs leveraging complement platform.
Challenges Ahead
- Continued quarterly net losses.
- High SG&A expense base.
- Ongoing R&D spending requirements.
- Interest expense impact on net results.
- Reliance on two primary commercial products.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...